Clinical trial · no report yet · Phase 1
NCT06115642
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
- NCT06115642 ↗
- Enrolling by invitation
- Shanghai Henlius Biotech
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced/Metastatic Solid Tumors
- Phase
- Phase 1
- Status
- Enrolling by invitation
- Conditions
- Advanced/Metastatic Malignant Solid Tumors
- Interventions
- HLX43; HLX10
- Arms
- Ia (Dose Escalation) · Experimental
- NSCLC failed to standard treatment (Part 2 Dose Expansion) · Experimental
- Thymic carcinoma (Part 2 Dose Expansion) · Experimental
- NSCLC failed to standard and docetaxel treatment (Part 2 Dose Expansion) · Experimental
- Stage IIIB, IIIC, or IV NSCLC without any prior treatment (Part 2 Dose Expansion) · Experimental
- Enrollment
- 367 (estimated)
- Primary outcomes
- The Dose-Limiting Toxicity (DLT) of HLX43 within 21 days after the first Administration
- Objective response rate (ORR)
- The maximum tolerated dose (MTD) of HLX43
- RP2D
- Sponsor
- Shanghai Henlius Biotech
- Start
- Nov 24, 2023
- Primary completion
- Jun 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06115642 · updated May 29, 2026